Owkin Becomes A Unicorn With $180 Million Investment From Sanofi

Owkin and Sanofi have announced that Owkin is now a unicorn – a startup valued at more than $1 billion – through a new $180 million investment from Sanofi. Sanofi will take a $180 million equity stake and alongside the investment, Owkin and Sanofi will enter a strategic multi-year collaboration to seek out new cancer therapies using AI. The project will focus on four types of cancer including non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma. They will use Owkin's predictive biomedical AI models to find new biomarkers and therapeutic targets. Owkin will also build prognostic models to predict how a patient will respond to a particular treatment.